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PhotoPoint Photodynamic Therapy
Promotes Stabilization of Atherosclerotic
Plaques and Inhibits Plaque Progression
Ron Waksman, MD,* Pauline E. McEwan, PHD,† Travis I. Moore, BS,† Rajbabu Pakala, PHD,*
Frank D. Kolodgie, PHD,‡ David G. Hellinga, MSC,* Rufus C. Seabron,* Steven J. Rychnovsky, PHD,†
Jeffrey Vasek, BENG,† Robert W. Scott, MD,† Renu Virmani, MD‡
Washington, DC; Santa Barbara, California; and Gaithersburg, Maryland
Objectives The purpose of this study was to determine how photodynamic therapy (PDT) promotes stabilization and reduc-
tion of regional atherosclerosis.
Background Photodynamic therapy, a combination of photosensitizer and targeted light to promote cell apoptosis, has been
shown to reduce atherosclerotic plaque inflammation.
Methods Forty New Zealand White rabbits were fed with cholesterol. The iliac arteries were balloon denuded and random-
ized to receive either PhotoPoint PDT treatment (photosensitizer and light) (Miravant Medical Technologies,
Santa Barbara, California), photosensitizer (MV0611) alone, or light alone and were then compared at 7 and 28
days. Arteries were examined for evidence of plaque volume, cell number, macrophage and smooth muscle cell
(SMC) content, and plaque cell proliferation.
Results Compared with contralateral iliac artery controls at 7 days, plaque progression was reduced by approximately
35% (p  0.01); plaque progression was further reduced to approximately 53% (p  0.01) by 28 days, leading
to an increase in lumen patency (p  0.05). At 7 days after PDT, percent plaque area occupied by macrophages
decreased by approximately 98% (p  0.001) and SMCs by approximately 72% (p  0.05). At 28 days after
PDT, removal of macrophages was sustained (approximately 92% decrease, p  0.001) and plaques were re-
populated with non-proliferating SMCs (approximately 220% increase, p  0.001). There was no evidence of
negative or expansive arterial remodeling, thrombosis, or aneurysm formation.
Conclusions Photodynamic therapy simultaneously reduces plaque inflammation and promotes repopulation of plaques with
a SMC-rich stable plaque cell phenotype while reducing disease progression. These early healing responses sug-
gest that PDT is a promising therapy for the treatment of acute coronary syndromes. (J Am Coll Cardiol 2008;
52:1024–32) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.06.023a
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pcute coronary syndrome arising from plaque rupture is
ne of the leading causes of cardiovascular-related mor-
ality (1– 4). In sudden coronary death and acute myo-
ardial infarction (AMI), lesions resembling plaque rup-
ure (thin-cap fibroatheroma, vulnerable plaque) have
een reported in other arterial sites remote from the
ulprit plaque (5,6). Chronic inflammation caused by
acrophage infiltration, foam cell formation, size of
ecrotic core, fibrous cap, and degradation of collagen are
ntrinsic to the natural history of symptomatic and
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Manuscript received March 27, 2008; revised manuscript received June 4, 2008,
ccepted June 6, 2008.symptomatic atherosclerotic disease. These vulnerable,
nstable plaques, however, are considered “rupture-
rone” because of the higher (10% to 15%) incidence of
epeat AMI in patients previously presenting with AMI
4,7). This evidence suggests that the genesis and etiol-
gy of plaque disease are complex and diverse. Human
See page 1033
laques vary morphologically in length, volume, location,
nd are composed of heterogeneous cellular components.
owever, plaque inflammation, degree of stenosis (1,7)
nd smooth muscle cell (SMC) composition (8,9) inde-
endently or collectively play a critical role in promoting
laque instability. Therefore, a versatile therapeutic par-
digm, which can be localized either to a region of the
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September 16, 2008:1024–32 Photodynamic Therapy and Atherosclerosislaque or to a length of artery with significant plaque
urden, to simultaneously reduce plaque inflammation
nd promote plaque healing and stabilization is required.
Photodynamic therapy (PDT) is being used as a treat-
ent modality for proliferative neoplasms (10–12) and
ge-related macular degeneration (13). Recently endovascu-
ar PDT has emerged as a promising therapy for the
reatment of restenosis after injury (14) and in short-term
tudies has shown efficacy in limiting atherosclerotic plaque
nflammation in animal models (15–18).
PhotoPoint PDT is a combination endovascular therapy
esigned to systemically deliver a photosensitizer drug
gallium chloride mesoporphyrin dimethyl ester that be-
ongs to the metallotetrapyrrollic group [MV0611]; Mira-
ant Medical Technologies, Santa Barbara, California) (18)
hat is capable of being taken up by macrophages and other
laque inflammatory cells. A light delivery catheter con-
ected to a laser light source is then guided to areas of
laque formation to provide localized activation of the
hotosensitizer, which in turn creates the formation of
inglet oxygen that induces localized cell apoptosis. In an
ninjured rat carotid artery model we characterized the
hotosensitizer (MV0611), optimal dose of the MV0611 (3
g/kg), the wave length (542 nm) of the light for an
dequate activation of the MV0611, and the dose of the
ight to detect optimal denucleation of the medial cells (17).
e also tested the efficacy of MV0611 in stented and
onstented native porcine coronary arteries (18). We then
ested the hypothesis that MV0611-PDT could signifi-
antly eliminate atherogenic cells in New Zealand White
NZW) rabbits with established lesions. The safe removal
f cells that are essential to the development of atheroscle-
osis could provide a valuable treatment strategy for the
nstable plaque.
ethods
nimal care and procedures were carried out in accordance
ith the guide for the care and use of laboratory animals.
orty adult male NZW rabbits weighing 3.5 to 4.0 kg
Robinson Services, Inc., Clemmons, North Carolina) were
sed for the study. Rabbits were fed an atherogenic diet (1%
holesterol; 6% peanut oil; Bio-Serve, Frenchtown, New
ersey) for 7 days followed by iliac artery endothelial
enudation. Rabbits were maintained on an atherogenic
iet for an additional 4 weeks after denudation to allow
laque development.
urgical procedure. Rabbits were sedated with an intra-
uscular injection cocktail containing ketamine, xylazine,
nd acepromazine (7:1:0.5). Anesthesia was sustained
hroughout treatment procedures with 1% to 3% isoflurane
elivered in oxygen (2.0 l/min). Animals were monitored
hroughout each procedure. A balloon dilation catheter
Swan-Ganz, Arrow International, Reading, Pennsylvania)
as guided through the descending aorta into the right andeft iliac arteries with guidewire assistance (Cordis, Miami takes, Florida) after arteriot-
my of the left common carotid
rtery. The balloon catheter was
laced with fluoroscopic guidance
diatrizoate meglumine sodium
ontrast. Mallinckrodt, Hazel-
ood, Missouri), inflated to 4
tmospheres (ATM) in right and
eft distal iliac arteries, and pulled
roximally by 2 cm to induce 2-cm
esions. The catheter was then re-
ositioned at the distal starting
oint, reinflated to 6 ATM, and
ulled back a second time for ef-
ective removal of the endothelium
nd disruption of the subintima.
reliminary drug and light dose
ptimization pilot study. Preliminary studies to character-
ze the nature of the photosensitizer (MV0611) and to find
he optimal dose of the effective photosensitizer (3 mg/kg),
he wave length (542 nm) of the light for an adequate
ctivation of photosensitizer, and the dose of the light to
etect optimal reduction of the plaques were described in
arlier studies (17,18). However, these studies were con-
ucted in the rat and the porcine models. To confirm that
he drug uptake pattern in the atherosclerotic rabbit model
s similar to that found in the pigs and rats (17,18), a
reliminary pilot study was conducted. The photosensitizer
V0611 (3 mg/kg intravenous [IV] bolus) was adminis-
ered to 6 cholesterol-fed rabbits with balloon-denuded iliac
rteries who were then incubated for 4, 8, and 24 h (n 
/group). After drug incubation, 1 rabbit from each group
as killed; an extra rabbit (cholesterol-fed and balloon-
enuded) without drug infusion served as an untreated
ontrol. The iliac arteries were snap-frozen in liquid nitro-
en and cryosectioned for the fluorescent detection of
V0611 in plaques. After incubation, iliac arteries of the 3
emaining rabbits were light-treated (542 nm green light,
V0611-PDT), harvested at 3 days after treatment, em-
edded in paraffin, sectioned, and examined for evidence of
ell depletion. Efficacy of treatment was established as
laque cell apoptosis (terminal deoxynucletidyl transferase-
ediated dUTP nick end labeling [TUNEL]) and macro-
hage cell depletion (RAM-11) throughout continuous
laque lengths of treated arteries. Miravant photosensitizer
ompound was detected in cryosections with a microscope
quipped with epifluorescence (Nikon, Melville, New
ork). Peak fluorescence was observed in macrophages
etween 8 and 24 h after injection and correlated with
aximum cell depletion.
V0611-PDT procedure. In all subsequent rabbits (n 
4), MV0611 (3 mg/kg IV bolus) was administered via the
ar vein 8 h before light administration. Under anesthesia, a
iravant light diffusing catheter (3 cm) was advanced via
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
ATM  atmospheres
EEL  external elastic
lamina
IEL  internal elastic
lamina
MV0611  Miravant
photosensitizer compound
NZW  New Zealand White
PDT  photodynamic
therapy
SMC  smooth muscle cellhe right carotid artery into iliac arteries with flexible
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Photodynamic Therapy and Atherosclerosis September 16, 2008:1024–32uidewire assistance. Angiography was used to place the
atheter entirely over the 2-cm plaques. To cover the entire
laque area and also to avoid geographic miss, a 3-cm-long
ight source was chosen. The light diffuser, connected to a
iode laser, delivered 18 J/cm2 of light over a period of 90 s
o activate MV0611 localized within the vessel wall. Con-
ralateral iliac arteries served as controls, whereby the light
atheter was placed in the arterial wall but not activated.
ight alone in the absence of MV0611 was administered to
separate cohort of 6 rabbits (n  12 arteries). The iliac
rtery was briefly occluded (90 s), before light activation or
ham treatment, by low pressure balloon inflation to help
emove blood and to provide a uniform treatment field.
fter catheter removal, an angiogram was obtained to
onfirm lumen patency. After surgery, rabbits were main-
ained under filtered light for 24 h. After PDT treatment,
abbits were maintained on a diet containing 0.05% choles-
erol until scheduled follow-up of the first group at 7 days (n
12 arteries MV0611 alone; n  12 arteries MV0611 and
ight; and n  6 arteries light alone) and the second group at
8 days (n  12 arteries MV0611 alone; n  12 arteries
V0611 and light; and n 6 arteries light alone). This dietary
trategy maintains circulating levels of cholesterol to sustain the
nflammatory stimulus required for plaque progression.
lasma cholesterol. Plasma samples were collected from
hole blood at baseline (before atherogenic diet), at endo-
helial denudation, at PDT treatment time, and at death for
he measurement of plasma cholesterol by colorimetric end
oint analysis (Antech, Lake Success, New York).
issue harvest. Rabbits were euthanized at either 7 or 28
ays after PDT after anesthesia with an overdose of potas-
ium chloride IV via the ear vein. The arterial tree was
erfused and fixed at 100 mm Hg, and samples comprising
he aortic bifurcation and iliac arteries were stored in 10%
eutral buffered formalin for 24 h, then processed and
mbedded in paraffin. Arteries were measured and cut just
istal to the internal iliac artery at the bifurcation at 3
ntervals with 3 to 4 segments at each interval and labeled as
roximal, mid-section, and distal.
istopathology and immunohistochemistry. Serial
ransverse arterial sections (5 m) were stained with hema-
oxylin and eosin to establish plaque nuclei content. Demar-
ations of the internal elastic membrane (IEL), external
lastic membrane (EEL), and lumen were determined with
ovat’s stain. Macrophages were detected after antigen
etrieval (0.01% protease, 20 min) with a monoclonal
ntibody to RAM-11 (Dako, Carpinteria, California) di-
uted 1:300 and 1:200 in 1% bovine serum albumin. Smooth
uscle cells were identified with a polyclonal antibody
irected against -actin (1:1,000, Sigma-Aldrich, St. Louis,
issouri). The cell proliferation marker Ki67 (1:250, Santa
ruz Biotechnology, Santa Cruz, California) was used to
dentify proliferating cells. The von Willebrand factor VIII
1:20, Sigma) was used to detect endothelium. All antigens
ere detected with standard peroxidase anti-peroxidasend/or immunoalkaline phosphatase techniques and usedither diaminobenzidine or AEC (Dako) substrate
hromogens.
UNEL. For the preliminary optimization study, plaque
ell apoptosis was observed in arteries by the TUNEL
echnique (TACS TdT Kit TA4627, R&D Systems, Min-
eapolis, Minnesota). Sections of rabbit spleen, stained in
arallel, served as external positive controls. Internal con-
rols comprised endonuclease pre-treatment of non–PDT-
reated iliac arterial sections (data not shown).
istomorphometry. A skilled computer operator blinded
o the study performed all morphometric measurements.
easurements of plaque area, IEL, EEL, and plaque cell
umber/unit area were obtained in 8 consecutive transverse
ections of proximal, midsection, and distal portions from
ach artery (n  12 arteries; 96 total segments/group), with
computerized image analysis system (IP-Lab Spectrum
mage processing software, Signal Analytics Corporation,
ienna, Virginia). Cell counts were obtained automatically
ith a threshold value and binary processing of positively
tained nuclei. Color digital images of a total of 32 sections/
rtery were assessed separately for quantification of areas
ccupied by RAM-11 (macrophages) and -actin (Bio-
uant, Nashville, Tennessee).
tatistical analysis. Data are presented as means  SD.
lasma cholesterol levels were analyzed by repeated measure
-way analysis of variance with Fisher protected least
ignificant difference. Because there were no statistical
ifferences in any of the parameters measured between
ight-only and drug-only controls, comparisons were made
nly between drug-only control and PDT treatment groups.
hese data were analyzed by the unpaired Student t test.
ignificance was established by a value of p  0.05.
Figure 1 Plasma Cholesterol Levels
Plasma cholesterol levels were measured in the plasma collected from the rabbits
before starting on the diet supplemented with cholesterol (0 week), at the time of
denudation (1 week), at the time of photodynamic therapy (PDT) treatment (6
weeks), and 7 or 28 days after PDT treatment (7 or 10 weeks). Note that levels
remain significantly elevated, despite a lowered maintenance diet of 0.05% dietary
cholesterol at 28 days. *p  0.001 compared with 0 weeks; p  0.001 com-
pared with 1 week; @p  0.01 compared with 6 weeks.
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lasma cholesterol. Baseline rabbit cholesterol values be-
ore receiving atherogenic diet were 44.5  19 mg/dl,
ncreasing after 1 week to 629  38 mg/dl at endothelial
enudation and after 5 weeks to 1,299  56 mg/dl at PDT
reatment time. At 7 days after PDT, the cholesterol values
ell to 1,100  21 mg/dl, then decreased further to 843 
01 mg/dl at 28 days after PDT and remained significantly
levated on the 0.05% maintenance cholesterol diet (Fig. 1).
DT tolerance. Three rabbits died during induction of
nesthesia. At autopsy, there was no evidence to suggest
essel toxicity that could relate the death to the photosen-
itizer. Electrocardiograms in all remaining rabbits were
ormal. After MV0611 administration, rabbits exhibited no
hysical or behavioral abnormalities, and histological anal-
sis of arteries showed no evidence of thrombosis, inflam-
ation, aneurysm formation, or adventitial fibrosis.
DT optimization pilot study. Progression of MV0611
rom adventitia to plaque was dependent on the duration of
Figure 3 Effect of PDT on Cell Depletion
(A) The effects of Miravant photosensitizer compound incubation time on cell
depletion throughout entire regional plaques. Note that maximum cell depletion
is observed at 8 and 24 h after injection. Also note, in rabbits killed at 3 days
after photodynamic therapy (PDT), evidence of significant plaque cell apoptosis
by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling
(black) staining (B) compared with contralateral untreated control (C).Figure 2 Tissue Localization of MV0611 Photosensitizer
Fluorescent localization of Miravant photosensitizer compound after incubation
at 0 (A), 4 (B), 8 (C), and 24 h (D). Note at 4 h there is evidence of photo-
sensitizer in media (M) and plaque (P). At 8 and 24 h after injection, photosen-
sitizer is present within plaque regions containing macrophages.
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Photodynamic Therapy and Atherosclerosis September 16, 2008:1024–32ncubation. Maximum detection of in-plaque macrophages
as observed between 8 and 24 h after injection. (Fig. 2)
he temporal and spatial distribution of MV0611 suggests
hotosensitizer delivery via the adventitial vaso vasora and
umen. After treatment with PDT, plaque cell loss increased
s a function of escalating drug incubation time throughout
ntire 2-cm lengths of concentric and eccentric plaques
Fig. 3). Maximum plaque cell depletion throughout entire
engths of plaque was observed with 24-h drug incubation
Fig. 3A). Plaque cell depletion with 8-h drug incubation
aried from 55% to 72% (few proximal sections at the lower
nd and most of the distal sections at the higher end), and
laque cell depletion with 24-h drug incubation varied from
4% to 100% (both maximal and distal sections at the
igher end and the middle sections at the lower end).
ecause variation between these 2 time points is not
tatistically significant and 8 h of incubation would be more
linically friendly, this time point for drug incubation was
elected for the rest of the studies.
ffect of PDT on plaque area. In 7- and 28-day controls,
-cm lengths of iliac artery contained single or multiple
ccentric and concentric luminal plaques. Despite lowering
he cholesterol diet to 0.05%, there was continued plaque
rowth in control arteries with some changes in cellular
omposition (0.05%). In any of parameters determined, the
alues between light-only and drug-only controls were not
tatistically different (data not presented). Contralateral
ontrol plaques that received no light increased from 0.48
.13 mm2 at 7 days to 0.79  0.03 mm2 at 28 days and
Figure 4 Effect of PDT on Vessel Parameters
Green bars are drug-only controls, whereas brown bars represent drug and light co
stenosis, plaque area, lumen area, and external elastic membrane area (n  12 a
percent stenosis (A), reduced plaque area (B), and increased lumen area (C) with noccupied up to 45% of the lumen area. Compared with
rug-only controls, plaque area in PDT animals was signif-
cantly smaller both at 7 days (0.31  0.08 mm2 in PDT vs.
.48  0.13 mm2 in MV0611 control, p  0.01) and 28
ays (0.37  0.05 mm2 in PDT vs. 0.79  0.03 mm2 in
V0611 control, p  0.01). At 28 days after treatment
ith PDT, plaque percent stenosis was significantly less
han that in 28-day controls (34.2  2.8% PDT vs. 45 
.1% MV0611 control and 42  2.9% light control, p 
.01 for both) (Fig. 4A). In PDT animals with a decrease in
laque area and plaque percent stenosis, lumen area in-
reased (0.77  0.08 mm2 in 7-day PDT treated vs. 1.02 
.03 mm2 in 28-day PDT treated, p  0.05) (Fig. 4C).
here was no significant effect of PDT on the EEL at either
or 28 days and, therefore, no evidence of negative or
xpansive arterial remodeling (Fig. 4D).
ffects of PDT on plaque histology and nuclei number. In
ontrol arteries harvested at 7 and 28 days, treatment with
V0611 alone or light alone had no effect on plaque nuclei
umber (Fig. 5A). After PDT treatment at 7 days, there
as a transient decrease in plaque nuclei number/mm2 of
laque compared with controls (756  320 PDT vs. 3,011 
12 MV0611 controls and 2,945  650 light controls, p 
.001 for both) (Figs. 5A, 5B, and 5D). By 28 days after
DT, plaque nuclei number was not different from
ontrols and cell counts in medial segments outside of the
-cm light treatment zone showed no evidence of injury
r cell proliferation due to catheter placement (Figs. 5A
nd 5C).
tion. Graphs A to D show the effects of photodynamic therapy (PDT) on plaque
/group). Note that by 28 days after treatment, PDT significantly reduced plaque
ce of negative or expansive arterial remodeling (D). *p  0.05; **p  0.01.mbina
rteries
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September 16, 2008:1024–32 Photodynamic Therapy and Atherosclerosislaque macrophage and SMC content. Because there is
o difference in the plaque nuclei number between light-
nly and drug-only controls, plaque macrophage and plaque
MC content was determined in the drug-only controls.
fter PDT treatment at 7 days, the percentage plaque area
ccupied by macrophages was significantly decreased com-
ared with controls (0.23  0.01 PDT treated vs. 14  2.2
ontrols, p 0.001) (Fig. 6A). The decrease in macrophages
as sustained at 28 days after PDT (0.74 0.02 PDT treated
s. 9.1  2.4 controls, p  0.001) (Figs. 6A, 7A, and 7F). At
days after PDT there is also a decrease in -actin positive
ells (6.1  1.8 PDT treated vs. 22  3.6 controls, p 
Figure 5 Changes in Plaque Nuclei Number/mm
2 of
Plaque in Response to Light, MV0611, and PDT
Blue bars represent light-only controls, green bars are drug-only controls, and
brown bars represent drug and light combination. Graph A shows initial (7
days) transient reduction in all atherogenic cells/mm2 of plaque followed by
plaque cell repopulation by 28 days (n  12 arteries/group). Photomicrographs
show hematoxylin and eosin staining of iliac arteries at 7 and 28 days after
photodynamic therapy (PDT) (B and C) versus controls (D and E). Note the
loss of “foam” cells at 28 days in panel C compared with controls. Magnifica-
tion 200. ***p  0.001..01) (Fig. 6B); however, at 28 days after PDT there is aignificant increase in -actin positive cells (42  7 PDT
reated vs. 13  3.4 controls, p  0.001) (Figs. 6B, 7B,
nd 7G).
laque healing and repair. At 28 days after PDT, plaques
omprised densely packed quiescent SMCs (Figs. 7B and
G). The Ki67 proliferation index (percent positive cells of
otal plaque cell number) of repopulated PDT treated
laques was less than controls (1.22  0.42 PDT treated vs.
.58  1.4 controls, p  0.01) (Figs. 7C and 7H). Staining
f random arterial sections with Factor VIII revealed the
resence of intact endothelium in both PDT-treated and
ontrol arteries at 28 days (Figs. 6D and 6J).
Figure 6 The Effects of PDT on Plaque Cell Composition
Green bars are drug-only controls, whereas brown bars represent drug and light
combination. Panel A shows that the area of plaque (mm2) occupied by macro-
phages is reduced by photodynamic therapy (PDT) at 7 days after treatment
and that macrophage removal is sustained at 28 days after PDT regardless of
elevated plasma cholesterol, an acute inflammatory stimulus (n  12 arteries/
group). Panel B shows transient loss of plaque smooth muscle cells/mm2 of
plaque at 7 days after PDT, followed by an increase in -actin area by 28 days,
indicative of plaque repopulation with a stable plaque cell phenotype (n  12
arteries/group). *p  0.05; ***p  0.001.
DO
i
p
v
c
t
t
a
a
p
p
S
t
n
r
o
C
l
p
s
r
(
t
g
c
M
o
t
fi
M
p
a
T
c
b
i
f
m
a
m
b
h
(
t
a
t
a
t
m
a
p
h
h
c
a
f
u
r
1030 Waksman et al. JACC Vol. 52, No. 12, 2008
Photodynamic Therapy and Atherosclerosis September 16, 2008:1024–32iscussion
ur findings in a cholesterol-fed balloon-denuded rabbit
liac artery model suggest that PhotoPoint PDT attenuates
laque progression with simultaneous plaque stabilization,
essel healing, and repair. At 7 days after treatment, PDT
aused a decrease in plaque macrophage cell content
hroughout the entire 2-cm balloon-injured and PDT-
reated vessel segment. This effect was sustained at 28 days
fter treatment. By 28 days after PDT, plaque matrix was
lmost entirely repopulated by -actin positive SMCs,
redictive of plaque stabilization and healing (19,20). Cell
roliferation analysis by Ki67 showed that only 1% of the
MCs were in G2 or S phases of the cell cycle, suggesting
hat at 28 days after PDT, the majority of plaque cells are
onproliferating with limited potential for plaque growth or
estenosis. Moreover, the endothelium, which was previ-
usly denuded, appeared intact at 28 days after PDT.
ollectively, the cellular changes induced by MV0611-PDT
ed to significantly reduced neointimal growth with com-
lete vascular healing.
A pivotal component of PDT in promoting plaque
tabilization is sustained macrophage removal. Cytokines
eleased by macrophages promote further atherogenesis
21,22) and continuous macrophage infiltration, which over
ime results in the accumulation of lipoproteins and aggre-
ation of free cholesterol that contribute to necrotic lipid
ore formation (23) leading to plaque instability (24).
oreover, release of macrophage metalloproteinases and
ther proteolytic enzymes is considered, in part, to weaken
he fibrous cap and promote plaque rupture (25,26). The
Figure 7 Serial Sections Showing a Rabbit Atherosclerotic Plaq
Photodynamic therapy (PDT) simultaneously reduced macrophages (A and F) and
non-G2 or S phases (C and H) as indicated by the Ki67 cell proliferation marker. A
presence of endothelium in PDT-treated arteries and controls (D and J) indicative
membrane and external elastic membrane with Movat’s stain. Note that plaque arnding that macrophage reinfiltration was prevented by lV0611-PDT treatment at 28 days is surprising, given that
lasma cholesterol levels, a potent stimulus for macrophage
ctivation, remained elevated until the time of sacrifice.
hese data suggest that factors other than cholesterol
ontribute to plaque macrophage infiltration and that sta-
ilizing effects of PDT on plaque matrix might selectively
nhibit macrophage migration. In vitro collagen gel studies,
or the purpose of understanding PDT mechanisms of cell
igration in restenosis, have shown that the effects of PDT
t the molecular level are complex. On the one hand, PDT
ight cross-link collagen (27), thus providing a temporary
arrier to invading SMCs (28). Yet at the same time, PDT
as been shown to promote accelerated endothelialization
29). Although it is possible that the reconstituted endo-
helium might be functionally altered to delay macrophage
dhesion and migration, the precise mechanisms of action
hat prevent the influx of macrophages into the intimal layer
re unclear.
A critical component of plaque healing and repair is
hat after treatment with MV0611-PDT, the intimal
atrix was repopulated by SMCs by 28 days, with an
bsence of macrophages. Although similar changes in
laque cell composition (favorable to plaque stabilization)
ave been reported in rabbits maintained on a 16-month
ypolipidemic diet (30), the rapid change in plaque
omposition induced by PDT is striking. Moreover,
lthough statins have shown long-term clinical efficacy
or reducing atherosclerosis in humans (31), they are
nsuitable for acute management of plaques that are
upture-prone (32). In contrast, the acute plaque stabi-
t 28 Days After PDT Treatment
d existing plaque matrix with quiescent smooth muscle cells (B and G) in the
ndothelial denudation of all rabbit arteries, staining with Factor VIII revealed the
rial repair by 28 days. Panels E and K show the presence of the internal elastic
ignificantly less than controls at 28 days after PDT. Magnification 200.ue a
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September 16, 2008:1024–32 Photodynamic Therapy and Atherosclerosisherapeutic benefit, because a complete change in plaque
ell composition was rapidly achieved by 28 days.
At 28 days after treatment, MV0611-PDT–treated arter-
es were significantly less occluded than untreated contralat-
ral control arteries. The MV0611-PDT achieved this by
educing neointimal growth, with a simultaneous change in
he plaque composition toward a stable plaque. Given that
hese effects were observed throughout the entire 2-cm
reated length of artery, these data suggest that PDT might
rove effective for the treatment of regional atherosclerosis
n humans. Moreover, systemic photosensitizer administra-
ion might allow for multiple vessel segment treatments
ithin a single intervention and might prove more cost-
ffective than the deployment of multiple stents. Also, from
 safety perspective, catheter removal after PDT treatment
ight avoid some of the pathological phenomena that are
ypically associated with stents, namely hypersensitivity, late
tage thrombosis, delayed healing, malapposition, resteno-
is, adventitial fibrosis, and impaired re-endothelialization
33,34). Moreover, a well-tolerated biological response with
ppropriate vessel healing might compare favorably with
rug-eluting stents that could be challenged in their capacity to
ocally deliver the combination of drugs required to reduce
nflammation yet promote healing and repair mechanisms.
Initially, photosensitizers were designed specifically for
he treatment of solid tumors and were designed to have
arge absorptions in the 620- to 740-nm range so as to
hoto-activate the drug that will penetrate to the greatest
epths possible in all tissue types. In particular these
hotosensitizers were designed to absorb outside of the
lood absorption spectrum profile, thus ensuring efficient
hotoactivation in most tissue types. When red light PDT
as used in cardiovascular disease, a high energy was used to
vercome the absorption in the blood that resulted in
hotochemically induced damage to normal myocardial
issue surrounding the artery (18). This adverse effect could
e the result of nonselective photosensitizer uptake and long
epths of red light penetration, which activates the photo-
ensitizer in the myocardial tissue. The use of a lower
avelength of light (600 nm) has a significant advantage,
ecause such wavelengths have penetration characteristics that
eliver the PDT effect to shallower tissue (plaque, media, and
dventitia) and not to deep myocardial tissue (18).
Clinical use of PDT therapy has been limited to non-
andomized, nonplacebo-controlled trials, with red light
ctivation of 5-aminolaevulinic acid at 630 nm or motexafin
utetium at 730 nm (35–38). Although motexafin lutetium
s well tolerated at lower doses, at higher doses a
ignificant number of patients had paraesthesia (38). The
se of deep penetrating red light might be better toler-
ted in peripheral vessels than in coronary vessels, where
DT with 5-aminolaevulinic acid has shown evidence of
yocardial scarring in porcine coronary arteries (39).
lthough the green light used in the current study
equires a blood free field to avoid absorption by circu-
ating red blood cells, the light exposure time using green
1ight (90 s) is significantly less than the time used for red
ight (12 min) in prior studies.
tudy limitations. The current study was carried out in
holesterol-fed balloon-denuded iliac arteries where the
athology of the plaque is not similar to that of human
laques. Moreover, this is a short-term study; thus, the
ong-term effect of MV0611-PDT treatment is not known.
onclusions
ur findings that removal of plaque inflammatory cells and
eplacement with SMCs promotes plaque stabilization as
arly as 28 days suggest a timely, effective, and appropriate
ascular healing and repair response after PDT treatment.
hotoPoint PDT could be an interesting intravascular
herapy for the treatment of acute coronary syndromes and
egional atherosclerosis.
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